PMID- 22928601 OWN - NLM STAT- MEDLINE DCOM- 20131028 LR - 20231212 IS - 1750-3639 (Electronic) IS - 1015-6305 (Print) IS - 1015-6305 (Linking) VI - 23 IP - 3 DP - 2013 May TI - Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. PG - 237-43 LID - 10.1111/j.1750-3639.2012.00630.x [doi] AB - Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high-grade astrocytomas (32 pediatric glioblastomas, 65 adult glioblastomas, 19 anaplastic astrocytomas) with known ALT status using tissue microarrays to identify associations with molecular and phenotypic features. Immunohistochemistry was performed using antibodies against ATRX, DAXX, p53 and IDH1(R132H) mutant protein. EGFR amplification was evaluated by fluorescence in situ hybridization (FISH). Almost half of fibrillary and gemistocytic astrocytomas (44%) demonstrated ALT. Conversely all gliosarcomas (n = 4), epithelioid (n = 2), giant cell (n = 2) and adult small cell astrocytomas (n = 7) were ALT negative. The ALT phenotype was positively correlated with the presence of round cells (P = 0.002), microcysts (P < 0.0002), IDH1 mutant protein (P < 0.0001), ATRX protein loss (P < 0.0001), strong P53 immunostaining (P < 0.0001) and absence of EGFR amplification (P = 0.004). There was no significant correlation with DAXX expression. We conclude that ALT represents a specific phenotype in high-grade astrocytomas with distinctive pathologic and molecular features. Future studies are required to clarify the clinical and biological significance of ALT in high-grade astrocytomas. CI - (c) 2012 The Authors; Brain Pathology (c) 2012 International Society of Neuropathology. FAU - Nguyen, Doreen N AU - Nguyen DN AD - Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Heaphy, Christopher M AU - Heaphy CM FAU - de Wilde, Roeland F AU - de Wilde RF FAU - Orr, Brent A AU - Orr BA FAU - Odia, Yazmin AU - Odia Y FAU - Eberhart, Charles G AU - Eberhart CG FAU - Meeker, Alan K AU - Meeker AK FAU - Rodriguez, Fausto J AU - Rodriguez FJ LA - eng GR - P30 CA006973/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120924 PL - Switzerland TA - Brain Pathol JT - Brain pathology (Zurich, Switzerland) JID - 9216781 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Co-Repressor Proteins) RN - 0 (DAXX protein, human) RN - 0 (Molecular Chaperones) RN - 0 (Nuclear Proteins) RN - EC 3.6.4.- (DNA Helicases) RN - EC 3.6.4.12 (ATRX protein, human) RN - EC 3.6.4.12 (X-linked Nuclear Protein) SB - IM MH - Adaptor Proteins, Signal Transducing/metabolism MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Astrocytoma/*pathology/ultrastructure MH - Brain Neoplasms/*pathology/ultrastructure MH - Child MH - Child, Preschool MH - Co-Repressor Proteins MH - DNA Helicases/metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Infant MH - Kaplan-Meier Estimate MH - Male MH - Microarray Analysis MH - Middle Aged MH - Molecular Chaperones MH - Nuclear Proteins/metabolism MH - Phenotype MH - Survival Analysis MH - Telomere/*pathology/ultrastructure MH - X-linked Nuclear Protein MH - Young Adult PMC - PMC3827727 MID - NIHMS448285 EDAT- 2012/08/30 06:00 MHDA- 2013/10/29 06:00 PMCR- 2012/09/24 CRDT- 2012/08/30 06:00 PHST- 2012/07/10 00:00 [received] PHST- 2012/08/16 00:00 [accepted] PHST- 2012/08/30 06:00 [entrez] PHST- 2012/08/30 06:00 [pubmed] PHST- 2013/10/29 06:00 [medline] PHST- 2012/09/24 00:00 [pmc-release] AID - BPA630 [pii] AID - 10.1111/j.1750-3639.2012.00630.x [doi] PST - ppublish SO - Brain Pathol. 2013 May;23(3):237-43. doi: 10.1111/j.1750-3639.2012.00630.x. Epub 2012 Sep 24.